Secukinumab for Psoriasis Treatment: A Case Series

Nopriyati, Radema Maradong

2018

Abstract

Psoriasis is a chronic inflammatory disease of the skin and nails, is characterized by erythematous plaques with silvery scale or pustules lesion for psoriasis pustular. Patients can suffer for psoriasis arthritis after the moderate to severe psoriasis occurred. Methotrexate remains a first line treatment for severe to moderate psoriasis, but due to the limitation of this medication, we decided to use secukinumab. We reported 2 patients. First case is a patient of psoriasis vulgaris with BSA of 20% and PASI 14.1 and history of cyclosporine A treatment for 3 months, the second case is a patient of psoriasis pustular with BSA of 22% and PASI 6 and history of methylprednisolone treatment for 6 months. First patient treated with 150 mg of secukinumab and the second patient treated with 300 mg of secukinumab. The result after 16 weeks treatment was satisfied which BSA and PASI was decreased. The efficacy of secukinumab should be considered for the treatment of moderate psoriasis.

Paper Citation

in Harvard Style

Nopriyati. and Maradong R. (2018). Secukinumab for Psoriasis Treatment: A Case Series.In Proceedings of the 23rd Regional Conference of Dermatology - Volume 1: RCD, ISBN 978-989-758-494-7, pages 496-499. DOI: 10.5220/0008160604960499

in Bibtex Style

@conference{rcd18,
author={Nopriyati and Radema Maradong},
title={Secukinumab for Psoriasis Treatment: A Case Series},
booktitle={Proceedings of the 23rd Regional Conference of Dermatology - Volume 1: RCD,},
year={2018},
pages={496-499},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0008160604960499},
isbn={978-989-758-494-7},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 23rd Regional Conference of Dermatology - Volume 1: RCD,
TI - Secukinumab for Psoriasis Treatment: A Case Series
SN - 978-989-758-494-7
AU - Nopriyati.
AU - Maradong R.
PY - 2018
SP - 496
EP - 499
DO - 10.5220/0008160604960499